Publications by authors named "H Westdorp"
Article Synopsis
- This study investigates the effectiveness and safety of a combination therapy using immune checkpoint inhibitors (ICIs) for certain subgroups of metastatic castration-resistant prostate cancer (mCRPC) patients who show an immunogenic profile.
- The trial involved 69 patients with specific genetic markers and assessed the disease control rate after treatment, aiming to exceed 22%.
- Results showed that 38% of patients achieved disease control beyond 6 months, with the highest success in patients with mismatch repair deficiency, but treatment led to significant side effects in some cases, with 20% permanently discontinuing therapy.
PSMA-targeting radioligand therapy (PSMA-RLT) has shown promise in metastatic castration-resistant prostate cancer (mCRPC), particularly in PSMA-avid tumours. However, predicting response remains challenging. Preclinical data suggests aberrant p53-signalling as a predictor of poor response.
View Article and Find Full Text PDFBackground: Metastatic endometrial cancer (mEC) continues to have a poor prognosis despite the introduction of several novel therapies including immune checkpoints inhibitors. Dendritic cell (DC) vaccination is known to be a safe immunotherapeutic modality that can induce immunological and clinical responses in patients with solid tumors. Platinum-based chemotherapy is known to act synergistically with immunotherapy by selectively depleting suppressive immune cells.
View Article and Find Full Text PDFPurpose: Pazopanib is known to cause liver toxicity. A relationship between pazopanib exposure and alanine transaminase elevations has been described in clinical trials. This study investigated the relation between pazopanib exposure and liver toxicity in real-world patients and evaluated the management of pazopanib-induced liver toxicity in routine care.
View Article and Find Full Text PDF